'Silent killer': the science of tracing climate deaths in heatwaves
The figure was supposed to "grab some attention" and sound a timely warning in the hope of avoiding more needless deaths, said Friederike Otto, one of the scientists involved in the research.
"We are still relatively early in the summer, so this will not have been the last heatwave. There is a lot that people and communities can do to save lives," Otto, a climate scientist at Imperial College London, told AFP.
Heat can claim tens of thousands of lives during European summers but it usually takes months, even years, to count the cost of this "silent killer".
Otto and colleagues published their partial estimate just a week after temperatures peaked in western Europe.
While the underlying methods were not new, the scientists said it was the first study to link heatwave deaths to climate change so soon after the event in question.
Early mortality estimates could be misunderstood as official statistics but "from a public health perspective the benefits of providing timely evidence outweigh these risks," Raquel Nunes from the University of Warwick told AFP.
"This approach could have transformative potential for both public understanding and policy prioritisation" of heatwaves, said Nunes, an expert on global warming and health who was not involved in the study.
- Big deal -
Science can show, with increasing speed and confidence, that human-caused climate change is making heatwaves hotter and more frequent.
Unlike floods and fires, heat kills quietly, with prolonged exposure causing heat stroke, organ failure, and death.
The sick and elderly are particularly vulnerable, but so are younger people exercising or toiling outdoors.
But every summer, heat kills and Otto -- a pioneer in the field of attribution science -- started wondering if the message was getting through.
"We have done attribution studies of extreme weather events and attribution studies of heatwaves for a decade... but as a society we are not prepared for these heatwaves," she said.
"People think it's 30 (degrees Celsius) instead of 27, what's the big deal? And we know it's a big deal."
When the mercury started climbing in Europe earlier this summer, scientists tweaked their approach.
Joining forces, Imperial College London and the London School of Hygiene & Tropical Medicine chose to spotlight the lethality -- not just the intensity -- of the heat between June 23 and July 2.
Combining historic weather and published mortality data, they assessed that climate change made the heatwave between 1C and 4C hotter across 12 cities, depending on location, and that 2,300 people had likely perished.
But in a notable first, they estimated that 65 percent of these deaths -- around 1,500 people across cities including London, Paris, and Athens -- would not have occurred in a world without global warming.
"That's a much stronger message," said Otto.
"It brings it much closer to home what climate change actually means and makes it much more real and human than when you say this heatwave would have been two degrees colder."
- Underestimated threat -
The study was just a snapshot of the wider heatwave that hit during western Europe's hottest June on record and sent temperatures soaring to 46C in Spain and Portugal.
The true toll was likely much higher, the authors said, noting that heat deaths are widely undercounted.
Since then Turkey, Greece and Bulgaria have suffered fresh heatwaves and deadly wildfires.
Though breaking new ground, the study has not been subject to peer review, a rigorous assessment process that can take more than a year.
Otto said waiting until after summer to publish -- when "no one's talking about heatwaves, no one is thinking about keeping people safe" -- would defeat the purpose.
"I think it's especially important, in this context, to get the message out there very quickly."
The study had limitations but relied on robust and well-established scientific methodology, several independent experts told AFP.
Tailoring this approach to local conditions could help cities better prepare when heatwaves loom, Abhiyant Tiwari, a health and climate expert who worked on India's first-ever heat action plan, told AFP.
"I definitely see more such studies coming out in the future," said Tiwari from NRDC India.
Otto said India, which experiences tremendously hot summers, was a "prime candidate" and with a template in place it was likely more studies would soon follow.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
an hour ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.

ABC News
7 hours ago
- ABC News
Great Barrier Reef coral cover decline shows 'ecosystem under stress'
Parts of the Great Barrier Reef have experienced the largest annual decline in coral cover in nearly 40 years, with experts warning it faces a future of "increased volatility". According to the latest annual survey from the Australian Institute of Marine Science (AIMS), hard coral cover declines in 2025 were largely driven by climate change-induced heat stress, leading to mass bleaching events and exacerbated by cyclones, floods, and outbreaks of crown-of-thorns starfish. While the coral losses were significant, they came off a high base, with observed coral cover now sitting at "near to long-term average levels". Rising ocean temperatures, floods, and cyclones were all compounding the impacts of recent bleaching events. "We are now seeing increased volatility in the levels of hard coral cover — this is a phenomenon that emerged over the last 15 years and points to an ecosystem under stress," Dr Emslie said. AIMS has been monitoring and surveying the Great Barrier Reef for 39 years. It noted the 2024 mass bleaching event was the fifth to hit the region since 2016, and the largest ever recorded on the Great Barrier Reef. The stunning, varied colour of the corals in the Great Barrier Reef is the result of a unique, symbiotic relationship between the hard coral and zooxanthellae algae. The coral gives the algae a protective environment, and the algae feeds the coral. But when the ocean gets too hot, the coral polyps can become stressed and expel the zooxanthellae, which triggers the bleaching effect. Without food for too long, the coral can starve and die. In the latest AIMS survey results, the most impacted coral species were the Acropora, which is susceptible to heat stress and a favoured food of the crown-of-thorns starfish. "These corals are the fastest to grow and are the first to go," Dr Emslie said. "This is also the first time we've seen substantial bleaching impacts in the southern region, leading to the largest annual decline since monitoring began." AIMS surveys 124 individual reefs across the Great Barrier Reef (GBR), and analyses results for three regions: the Northern GBR from Cape York to Cooktown, Central GBR from Cooktown to Proserpine, and Southern GBR from Proserpine to Gladstone. One of the main measures used to monitor the condition of the reef is the percentage of hard coral cover, which describes the proportion of the sea floor that is covered in hard coral. Compared to figures from 2024, the Southern GBR saw a 30 per cent decline in coral cover — the largest annual decline ever recorded, bringing it below the long-term average. Coral cover in the Central and Northern GBR remains above long-term averages, but both regions saw significant declines compared to 2024, of 14 per cent and 25 per cent respectively. Based on historical surveys, AIMS defines reefs with between 30-50 per cent coral cover as "high value" — that is, they're relatively healthy. Of the reefs surveyed, AIMS found that two had less than 10 per cent coral cover, 77 between 10 and 30 per cent cover, 33 between 30 and 50 per cent cover, 10 between 50 and 75 per cent cover, and two had greater than 75 per cent coral cover. While there has been an overall decline, the Great Barrier Reef has "fared relatively better" than other parts of the world because of its size and its varied habitats. The Caribbean, for example, has suffered high mortality on almost all of its reefs, and very little coral remains. "The Great Barrier Reef currently retains higher coral cover than many reefs globally; however, mass coral bleaching events are now occurring with increasing frequency, while recovery periods are decreasing," the report said. One of the successes noted in the survey was the ongoing efforts to monitor and control crown-of-thorns starfish. Crown-of-thorns starfish can grow up to 80 centimetres in diameter, with up to 21 arms covered in hundreds of toxin-tipped thorns, and they can consume vast amounts of coral. The starfish are native to the Great Barrier Reef, but since the 1960s their numbers have increased significantly. Exactly what is behind the booming population is still being studied, but increased nutrient availability from land run-off, which increases phytoplankton, has created more food for COTS larvae, and may be leading to more adults. Over the past year, the federal government's crown-of-thorns starfish control program has culled over 50,000 starfish, injecting them with vinegar or ox bile. "Due to crown-of-thorns starfish control activities, there were no potential, established, or severe outbreaks of crown-of-thorns starfish recorded on Central GBR reefs in 2025," the AIMS report noted. As global carbon emissions continue to rise, so too does the temperature of the sea water that covers the Great Barrier Reef. The latest reef update from the Reef Authority shows that even as water temperatures declined during winter, they were still around 0.8 degrees above the long-term average. Earlier this year, the GBR experienced its sixth mass bleaching event since 2016. Up until the 1980s, coral bleaching at this scale was rare. "This year, Western Australian reefs also experienced the worst heat stress on record. It's the first time we've seen a single bleaching event affect almost all the coral reefs in Australia," AIMS CEO Selina Stead said. "Mass bleaching events are becoming more intense and are occurring with more frequency, as evidenced by the mass bleaching events of 2024 and 2025." This was the second time in the past decade that a reef experienced back-to-back bleaching events in consecutive years. Coral reef systems can take up to 10-15 years to recover. "The results from this year really underscore the amount of stress the Great Barrier Reef is under," Dr Emslie said.

The Australian
21 hours ago
- The Australian
Heart disease: What cardiologists do to protect themselves
We are all aware of basic matters of the heart, that its normal healthy functioning can be harmed by big risk factors such as smoking and drinking, being overweight and underactive, making poor dietary choices and having high blood pressure. Over time, one or more of these can contribute to the narrowing of the arteries as fatty materials (called atheroma) such as cholesterol accumulate inside them. It is when arteries become narrowed by plaque to the extent that blood flow to the heart and brain is restricted that heart disease is diagnosed. Yet most cases – the British Heart Foundation says about 70 per cent – are preventable and cardiologists are convinced that if more of us were aware of the simple steps we can take to reduce our risk, the death toll would fall. 'By managing their lifestyle risk factors and keeping tabs on health, people can dramatically reduce their risk of heart disease,' says Oliver Guttman, consultant cardiologist at the HCA Wellington Hospital in London. 'This is true even for those who currently feel well, as early metabolic changes often occur silently.' Coronary heart disease (CHD) remains one of the biggest killers in the UK, responsible for more than 66,000 deaths a year, with one person dying every eight minutes. It is the single biggest killer disease for men – one in eight dying from CHD – but the mistaken perception that heart attacks are not a big risk for women costs lives. According to the British Heart Foundation, heart disease kills more women each year than breast cancer, with signs from studies that cases are rising among women under 65. The BHF forecasts there could be one million more people living with heart disease in the UK by 2030. So, what are the rules for heart disease prevention? Here, Guttman and Hannah Douglas, consultant cardiologist at Guy's and St Thomas' NHS Foundation Trust, spell out their evidence-based recommendations. 1. Check your blood pressure at least once a year Blood pressure is one of the most important controllable risk factors for cardiovascular disease, yet hypertension is ignored or remains undiagnosed. A normal or ideal adult pressure is considered to be between 90/60mmHg and 120/80mmHg. 'Blood pressure is critically important and is truly a 'silent killer',' Douglas says. 'High blood pressure puts the entire vascular system under constant pressure and is a very significant risk factor for heart disease.' Having your blood pressure checked by your local pharmacy free of charge is the first step to take. Also investing in a home DIY monitor is an option and the BHF has a list of approved devices ( Blood pressure does ebb and flow, so a one-off high reading is usually nothing to worry about, but if it remains high for two or three weeks, see your doctor or nurse. 'Weight management and regular exercise are two of the easiest lifestyle methods that we know help to manage blood pressure,' Douglas says. 'But sustained high blood pressure should always be treated to reduce risk.' 2. Consider wearing a tracker if over 65 Devices such as smartwatches with ECG features, such as the Apple Watch and Fitbit, can be useful for detecting atrial fibrillation (AFib), an irregular heart rhythm that increases the risk of stroke and can contribute to heart failure. 'For people over 65 or those with symptoms such as palpitations or dizziness, these tools may help flag episodes of AFib early,' Guttman says. 'Do be aware that they can also give false positives, so any alerts should be followed up with proper clinical assessment.' Routine monitoring for most under-65s is not necessary, he says, but if you are concerned about AFib speak to your GP: 'These trackers are best thought of as screening tools, not diagnostic devices, and their usefulness increases with age.' 3. Get your cholesterol levels checked Measuring cholesterol and blood triglycerides – or your lipid profile – should be done every four to six years if you are someone considered at low risk of CHD. 'You will need to have it checked more often if your lipid profile is abnormal, you are genetically at a high risk of raised cholesterol or if you are on medication,' Guttman says. Finger-prick cholesterol checks can be carried out by your GP or local pharmacy, or as part of the National Health Service health check in England. According to the BHF, below 4mmol/L (below 2.6mmol/L if you have had a heart attack) is a healthy level of non-HDL, bad cholesterol, the type that builds up in your arteries. Above 1mmol/L is a healthy level of good HDL cholesterol for men and above 1.2mmol/L is a healthy level for women. Healthy total cholesterol levels are below 5mmol/L (4mmol/L if you've had a heart attack). 4. Eat a diet rich in anti-inflammatory whole foods 'Chronic inflammation is one of the key drivers of atherosclerosis, the plaque build-up in arteries,' Guttman says. 'A diet rich in anti-inflammatory whole foods is ideal for helping to prevent this and is not only heart-protective but supports gut health, brain function and long-term weight management.' He recommends a Mediterranean-style diet with vegetables, fruits, whole grains, legumes, healthy fats, particularly extra virgin olive oil, and nuts, and a regular consumption of fish and seafood, high in heart-healthy omega-3 fats. A review of clinical evidence in the journal Nutrients showed the approach is beneficial in reducing inflammation that is a risk factor for CHD. 'By also reducing or eliminating ultraprocessed, pre-packaged foods such as ready meals from the diet, we instead use more whole ingredients to cook at home, so it is an important step to take,' Douglas says. 'Whole food ingredients are going to be largely anti-inflammatory provided we balance the food groups and take care with not adding too much extra fat and salt.' 5. Don't neglect cardio at the gym Given its benefits for muscles, bones and the waistline, there is a trend for favouring weight training over cardiovascular exercise among the over-50s. But Douglas stresses that one is not necessarily better than the other for the heart. 'I tend to advise a 50:50 mix of cardio and light weight training for optimum cardiovascular health. 'Weight training has many benefits for blood pressure, general vascular health and bone density, but keeping active with cardiovascular or aerobic exercise is amazing for heart rate and blood pressure optimisation, weight management and has the secondary benefits of reducing the risk of other conditions such as type 2 diabetes, which in itself is closely linked with poor heart health.' Guttman says that, as a minimum, we should aim for the government targets of at least 150 minutes of moderate aerobic activity per week, and muscle-strengthening activities on two or more days per week. 'A mix of the two offers the best protection for cardiovascular and overall health,' he says. 6. Measure your waist circumference Being overweight is a risk factor for CHD, but central adiposity – fat around the middle – is generally more telling than the scales. Getting a tape measure out every 4-6 weeks is the best approach. 'The body mass index [BMI] is still commonly used, but it doesn't reflect body composition or fat distribution,' Guttman says. 'For most people, keeping an eye on waist circumference is the easiest and most reliable way to monitor central fat, which is metabolically harmful and strongly linked to CHD risk.' High-risk waist measurements are over 102cm (40in) for men and over 88cm (35in) for women, although the numbers shouldn't be taken in isolation. Douglas says: 'We know that waist circumference has been linked with cardiovascular risk, so is definitely a useful gauge, but for those at higher risk of CHD an approach agreed between you and your clinician is best.' 7. Do focus on healthy sleep patterns Sleep is a key component in managing general health. 'There are very few conditions, medical, physical and psychological, that aren't worsened by poor sleep,' Douglas says. 'This definitely includes heart disease.' Poor or insufficient sleep is associated with high blood pressure, obesity, type 2 diabetes and irregular heart rhythm, all risk factors for CHD. 'Sleep apnoea, which causes pauses in breathing during sleep, is another serious and underdiagnosed condition that significantly raises cardiovascular risk,' Guttman says. 'Most adults need 7 to 9 hours of good-quality sleep per night and prioritising a regular sleep schedule, reducing evening screen time, and managing stress can all help improve your sleep and consequently support heart health.' 8. Stop smoking and vaping Smoking remains one of the most powerful preventable risk factors for heart disease. 'It damages the arteries, increases blood pressure, promotes blood clotting and accelerates plaque build-up,' Guttman says. 'Even light or occasional 'social' smoking and passive smoking increase CHD risk.' There is no safe form of smoking. Research presented to the American Heart Association by cardiologists at the University of Wisconsin reported significant negative heart health impacts after vaping and smoking cigarettes. Immediately after vaping or smoking, increases in blood pressure, heart rate and blood vessel constriction were identified, and users of e-cigarettes performed worse than non-nicotine users on treadmill tests used to predict CHD risk. 'I do worry about the long-term effects of vaping,' Douglas says. 'Although easier said than done, all smokers need to work their hardest to become ex-smokers, with any support available.' The heart benefits of quitting begin within days, and over time the risk of CHD can fall to near that of a non-smoker. 9. Do discuss your family history of CHD Most CHD risk comes from a combination of genes and lifestyle. If you have a family history of heart disease, Guttman says you should always discuss with your GP or cardiologist whether additional testing is appropriate for you. 'Genetic testing can be helpful, especially in cases of strong family history of premature heart disease [heart attack or stroke before age 55 in men or 65 in women],' he says. 'Certain inherited conditions, such as familial hypercholesterolaemia, which is characterised by very high levels of non-HDL cholesterol in the blood, greatly increase heart disease risk and often go undiagnosed without testing.' However, routine genetic screening is not recommended. 'In asymptomatic patients it often raises more questions than it answers, unfortunately,' Douglas says. And even if you do have a genetic predisposition, there is no escaping the truth that healthy behaviours – not smoking, regular exercise, a balanced diet – will significantly reduce your CHD risk. 'Always discuss concerns with your GP or cardiologist, who will help to determine whether testing is appropriate for you,' Douglas says. 10. Women – be extra aware of symptoms around the menopause Menopause is a key window for reassessing heart health and 'it's an ideal time for women to get their blood pressure, cholesterol and glucose checked to ensure they're on track for the years ahead', Guttman says. Some of the symptoms associated with the perimenopause and menopause, including sweating, palpitations, breathlessness, intolerance of exercise and panic attacks, are also symptoms of heart disease and can get overlooked. 'Understanding signs that can be associated with fluctuating hormone levels is key to recognising the difference between perimenopause and, for example, a cardiac arrhythmia,' Douglas says. 'Women should always seek medical help for worrying symptoms early. And if not satisfied with the outcome, seek a second opinion.' HRT isn't prescribed to prevent CHD, but it may play a helpful role in managing menopausal symptoms in some women. For some of those under 60 or within 10 years of their menopause who are otherwise healthy, it may improve quality of life as well as improving some metabolic risk factors. 'I am a proponent of HRT for many peri and post-menopausal women for whom benefit outweighs risk,' Douglas says. However, HRT is not suitable for everyone, particularly women with a history of stroke, blood clots or known CHD. 'Decisions about HRT should be personalised, weighing the risks and benefits with a healthcare professional,' Guttman says. The Times Read related topics: HealthHeart